Haloduracin α Binds the Peptidoglycan Precursor Lipid II with 2:1 Stoichiometry
Open Access
- 17 October 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 133 (44) , 17544-17547
Abstract
The two-peptide lantibiotic haloduracin is composed of two post-translationally modified polycyclic peptides that synergistically act on Gram-positive bacteria. We show here that Halα inhibits the transglycosylation reaction catalyzed by PBP1b by binding in a 2:1 stoichiometry to its substrate lipid II. Halβ and the mutant Halα-E22Q were not able to inhibit this step in peptidoglycan biosynthesis, but Halα with its leader peptide still attached was a potent inhibitor. Combined with previous findings, the data support a model in which a 1:2:2 lipid II:Halα:Halβ complex inhibits cell wall biosynthesis and mediates pore formation, resulting in loss of membrane potential and potassium efflux.Keywords
Funding Information
- National Institutes of Health
This publication has 39 references indexed in Scilit:
- Sublancin is not a lantibiotic but an S-linked glycopeptideNature Chemical Biology, 2011
- Insights into the Mode of Action of the Two-Peptide Lantibiotic HaloduracinACS Chemical Biology, 2009
- Structure-Activity Relationship Studies of the Two-Component Lantibiotic HaloduracinChemistry & Biology, 2008
- Microtiter plate bioassay to monitor the interference of antibiotics with the lipid II cycle essential for peptidoglycan biosynthesisJournal of Microbiological Methods, 2008
- In Vitro Reconstitution and Substrate Specificity of a Lantibiotic ProteaseBiochemistry, 2008
- Discovery and in vitro biosynthesis of haloduracin, a two-component lantibioticProceedings of the National Academy of Sciences, 2006
- Lipid II-Based Antimicrobial Activity of the Lantibiotic Plantaricin CApplied and Environmental Microbiology, 2006
- Sequential Actions of the Two Component Peptides of the Lantibiotic Lacticin 3147 Explain Its Antimicrobial Activity at Nanomolar ConcentrationsAntimicrobial Agents and Chemotherapy, 2005
- Isolation and structural characterization of epilancin 15X, a novel lantibiotic from a clinical strain of Staphylococcus epidermidisFEBS Letters, 2005
- Biosynthesis and Mode of Action of LantibioticsChemical Reviews, 2005